Quoin Pharmaceuticals, Ltd. - American Depositary Shares (QNRX)
0.2995
+0.0043 (1.46%)
Quoin Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for rare and specialty diseases
The company specializes in creating and advancing treatments that address unmet medical needs, particularly in the areas of dermatology and other niche therapeutic segments. Through its research and development efforts, Quoin aims to provide effective solutions that improve patient outcomes and enhance the quality of life for those affected by challenging health conditions. The company's approach combines scientific expertise with a commitment to bringing new medications to market, fostering collaborations within the healthcare community to drive forward its mission.
Stay updated with the latest market activity on Thursday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
LAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and development company, with proprietary Invisicare® drug delivery technology, today announces significant achievements in 2024 and 2025, through its licensee Quoin Pharmaceuticals' progress in Netherton Syndrome treatment.
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
